DCT

1:25-cv-01306

Pfizer Inc v. Apotex Inc

Log In
Key Events
Amended Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:25-cv-01306, D. Del., 09/02/2026
  • Venue Allegations: Venue is alleged to be proper in the District of Delaware because Defendants Apotex Corp. and DifGen are Delaware corporations, and Defendant Apotex Inc., a Canadian corporation, is subject to personal jurisdiction in the district and regularly engages in patent litigation there.
  • Core Dispute: Plaintiffs allege that Defendants' submission of an Abbreviated New Drug Application (ANDA) to the FDA for a generic version of the drug Vyndamax® (tafamidis) constitutes an act of infringement of a patent covering specific crystalline forms of the active ingredient.
  • Technical Context: The lawsuit concerns pharmaceutical polymorphism, a field focused on identifying and characterizing specific solid-state crystal structures of a drug molecule, which can significantly impact the drug's stability, manufacturability, and therapeutic performance.
  • Key Procedural History: This is a Hatch-Waxman action triggered by a notice letter from Apotex, informing Plaintiffs of its ANDA filing. As part of its ANDA, Apotex filed a "Paragraph IV" certification asserting that U.S. Patent No. 9,770,441 is invalid, unenforceable, and/or will not be infringed by its proposed generic product.

Case Timeline

Date Event
2014-09-08 U.S. Patent No. 9,770,441 Priority Date
2017-09-26 U.S. Patent No. 9,770,441 Issue Date
2025-09-09 Apotex sends Notice Letter to Pfizer regarding ANDA submission
2026-04-09 DifGen announces prior FDA approval for a different product in partnership with Apotex
2026-09-02 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 9,770,441 - "CRYSTALLINE SOLID FORMS OF 6-CARBOXY-2-(3,5-DICHLOROPHENYL)-BENZOXAZOLE"

  • Patent Identification: U.S. Patent No. 9,770,441, "CRYSTALLINE SOLID FORMS OF 6-CARBOXY-2-(3,5-DICHLOROPHENYL)-BENZOXAZOLE," issued September 26, 2017.

The Invention Explained

  • Problem Addressed: The patent's background explains that for a pharmaceutical compound, different physical solid forms, known as polymorphs, can exist ʼ441 Patent, col. 9:35-42 These different forms can have distinct physical properties, such as stability and dissolution rate, which can impact the safety, efficacy, and manufacturability of a drug product ʼ441 Patent, col. 9:48-54 The process of finding and selecting an optimal, consistent solid form is described as unpredictable ʼ441 Patent, col. 10:5-9
  • The Patented Solution: The invention claims to have discovered and characterized specific, stable crystalline solid forms of the compound 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole, also known as tafamidis ʼ441 Patent, abstract These forms, particularly one designated "Form 1," are defined by a unique set of analytical data, including specific peaks in powder X-ray diffraction (PXRD) patterns, solid-state Nuclear Magnetic Resonance (NMR) spectra, and Raman spectra ʼ441 Patent, col. 2:7-15 By identifying these specific forms, the invention provides a path to a more reliable and consistent pharmaceutical product ʼ441 Patent, col. 10:46-53
  • Technical Importance: Identifying a stable, high-purity crystalline form is a critical step in drug development, ensuring that each batch of the drug has predictable properties and behaves consistently when administered to patients.

Key Claims at a Glance

  • The complaint asserts infringement of claims 1-16 of the '441 patent Compl. ¶57
  • Independent claim 1 is a composition claim for a specific crystalline form of the drug, defined by a Markush group of analytical parameters:
    • A crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole,
    • wherein said crystalline form has an analytical parameter selected from the group consisting of:
      • a solid state NMR spectrum comprising 13C chemical shifts (ppm) at 120.8±0.2 and 127.7±0.2,
      • a powder X-ray diffraction pattern comprising a peak at a diffraction angle (2θ) of 28.6±0.2, and
      • a Raman spectrum comprising a Raman shift peak (cm⁻¹) at 1292±2.
  • The complaint also highlights independent claim 15 (a pharmaceutical composition comprising the form of claim 1) and independent claim 16 (a method of treating disease by administering the form of claim 1) Compl. ¶¶61-64

III. The Accused Instrumentality

Product Identification

The accused instrumentality is "Apotex's ANDA Product," a proposed generic version of Vyndamax® (tafamidis) 61 mg capsules Compl. ¶1 Compl. ¶44

Functionality and Market Context

The product is a pharmaceutical capsule containing tafamidis as its active ingredient Compl. ¶43 Compl. ¶59 It is intended for the treatment of cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis, a condition for which the branded version, Vyndamax®, is approved Compl. ¶42 The complaint alleges that Defendants' proposed product contains a crystalline form of tafamidis that infringes the ’441 patent and will compete directly with Plaintiffs' branded product upon receiving FDA approval (Compl. ¶¶1-2; Compl. ¶60).

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

’441 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A crystalline form of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole... The complaint alleges that "Apotex's ANDA Product contains tafamidis, i.e., 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole," and that it is present in a crystalline form. ¶59; ¶60 col. 1:20-41
...wherein said crystalline form has an analytical parameter selected from the group consisting of a solid state NMR spectrum comprising 13C chemical shifts (ppm) at 120.8±0.2 and 127.7±0.2, a powder X-ray diffraction pattern comprising a peak at a diffraction angle (2θ) of 28.6±0.2, and a Raman spectrum comprising a Raman shift peak (cm⁻¹) at 1292±2. The complaint alleges on information and belief that the crystalline form of tafamidis in the ANDA product "has a solid state NMR spectrum ... at 120.8±0.2 and 127.7±0.2, a powder X-ray diffraction pattern ... at 28.6±0.2, or a Raman spectrum ... at 1292±2." The allegation mirrors the "or" structure of the Markush claim. ¶60 col. 2:26-62

Identified Points of Contention

  • Technical Question: A central factual question is whether the specific crystalline form of tafamidis manufactured for Apotex's ANDA Product actually possesses one or more of the precise analytical characteristics (NMR, PXRD, or Raman signals) required by claim 1. The complaint makes this allegation "on information and belief," and its verification will depend on discovery and detailed scientific testing of the accused product.
  • Scope Questions: The infringement analysis may focus on the interpretation of the numerical ranges specified in the claims (e.g., "±0.2" ppm for NMR, "±0.2" degrees for PXRD). A dispute could arise over whether the measured values for the accused product fall within these ranges, and how measurement variability, which is acknowledged in the patent ʼ441 Patent, col. 11:33-45, affects the infringement analysis.

V. Key Claim Terms for Construction

  • The Term: "crystalline form ... has an analytical parameter selected from the group consisting of..."
  • Context and Importance: This Markush group language is the core of the invention's definition and the primary basis for the infringement allegation. The dispute hinges on whether the accused product meets at least one of the three alternative analytical criteria. The construction of the numerical values and their associated error margins (e.g., "120.8±0.2") will be dispositive.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: Plaintiffs may argue that the patent's explicit mention of measurement variability (e.g., PXRD peak positions showing variability "typically as much as 0.1 to 0.2 degrees") supports a standard interpretation of the "±0.2" ranges as written, intended to capture minor instrumental and experimental fluctuations ʼ441 Patent, col. 11:36-39
    • Evidence for a Narrower Interpretation: Defendants may argue that the patent's detailed description of the specific equipment and conditions used to generate the data ʼ441 Patent, col. 12:46-67 limits the claim to results obtained under highly similar measurement conditions. They might contend that any ambiguity in the range should be resolved narrowly, or that their product's characteristics, while close, fall definitively outside the claimed ranges when properly measured.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges induced infringement, stating that the proposed labeling for Apotex's ANDA Product will direct and encourage physicians and patients to use the product in a manner that infringes method claim 16 Compl. ¶64 Compl. ¶69 It also alleges contributory infringement, asserting the product is not a staple article and is especially adapted for an infringing use Compl. ¶70
  • Willful Infringement: The complaint alleges that Defendants acted with full knowledge of the '441 patent, based on the fact that Apotex filed a Paragraph IV certification with the FDA specifically addressing the patent Compl. ¶56 Compl. ¶73 This forms the basis for the allegation that any subsequent infringement would be willful.

VII. Analyst’s Conclusion: Key Questions for the Case

The resolution of this case will likely depend on the answers to two primary questions:

  1. A question of scientific fact: Does the crystalline form of tafamidis in Apotex’s proposed generic product, when subjected to analytical testing (PXRD, ssNMR, Raman), exhibit one of the specific spectral or diffraction "fingerprints" recited in claim 1 of the '441 patent? This is a classic pharmaceutical polymorph dispute that will be driven by expert analysis of competing laboratory data.
  2. A question of definitional scope: How should the court construe the numerical ranges (e.g., "28.6±0.2") that define the patented crystalline form? The case may turn on the degree to which these ranges account for standard measurement error, and whether the accused product's properties fall inside or outside those legally defined boundaries.